Zonisamide for Weight Reduction in Obese Adults

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00275834
First received: January 10, 2006
Last updated: February 7, 2013
Last verified: February 2013
Results First Received: December 10, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Obesity
Intervention: Drug: Zonisamide

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo No text entered.
Zonisamide 200 mg No text entered.
Zonisamide 400 mg No text entered.
Total Total of all reporting groups

Baseline Measures
    Placebo     Zonisamide 200 mg     Zonisamide 400 mg     Total  
Number of Participants  
[units: participants]
  74     76     75     225  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     74     76     75     225  
>=65 years     0     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  43.5  ± 10.3     44.2  ± 10.1     42.3  ± 10.0     43.4  ± 10.1  
Gender  
[units: participants]
       
Female     44     45     45     134  
Male     30     31     30     91  
Region of Enrollment  
[units: participants]
       
United States     74     76     75     225  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Body Weight   [ Time Frame: 1 year ]

2.  Secondary:   Proportions of Patients With 5% Weight Loss   [ Time Frame: 1 year ]

3.  Secondary:   Proportions of Patients With 10% Weight Loss   [ Time Frame: 1 year ]

4.  Secondary:   Waist Circumference   [ Time Frame: 1 year ]

5.  Secondary:   Inflammatory Markers   [ Time Frame: 1 year ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Lipids   [ Time Frame: 1 year ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Quality of Life   [ Time Frame: 1 year ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

8.  Secondary:   Psychological Measures   [ Time Frame: 1 year ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

9.  Secondary:   Blood Pressure   [ Time Frame: 1 year ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Kishore Gadde
Organization: Duke University Medical Center
phone: 919-668-0208
e-mail: kishore.gadde@duke.edu


Publications:

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00275834     History of Changes
Other Study ID Numbers: Pro00005514/67352, R01DK067352, 1-RO1-DK067352
Study First Received: January 10, 2006
Results First Received: December 10, 2012
Last Updated: February 7, 2013
Health Authority: United States: Food and Drug Administration
United States: Federal Government